Efficient Trafficking of Chimeric Antigen Receptor
(CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL [poster presentation].
The Chimeric Antigen Receptor
(CAR)-T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015 Report gives insights on 35 products targeting 20 different antigens and 9 different technologies.
CAR T cell Genetically engineered T cells with surface receptors (called chimeric antigen receptors
or CARs) that bind to a specific antigen on tumor cells.
genes: structure, function, and techniques for analysis of their rearrangements.
The T Cells were transfected with messenger RNA (mRNA) encoding for chimeric antigen receptor
(CAR) molecules that target specific cell surface markers on tumor cells.
By Product Segment : Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor
(CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors.
The study, published July 20, 2009, in Blood, shows that African-Americans with HIV who possess both a variation in the gene for the Duffy antigen receptor
for chemokine (DARC) and leukopenia have slower HIV-to-AIDS progression rates than HIV-infected European-Americans with leukopenia.
Altor has already successfully improved and converted the licensed TCRs into targeted therapeutic reagents using its Soluble T-cell Antigen Receptor
6, 2015 /PRNewswire/ -- Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor
T cell (CART) therapy CTL019 in certain types of relapsed or refractory (r/r) non-Hodgkin lymphoma will be presented in an oral session at the 57th American Society of Hematology (ASH) annual meeting.
With four candidates currently in clinical trials and five more agents expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the body's immune system to combat cancers that includes novel checkpoint inhibitors, chimeric antigen receptor
T-cell (CART) technology, myeloid cell targeting agents, and STING agonists.
TNK(TM) (Chimeric Antigen Receptor
Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases.
About Chimeric Antigen Receptor
and High-affinity T Cell Receptor Approaches
BioTransplant says MEDI-507 is a humanized monoclonal antibody that binds specifically to the CD2 antigen receptor
found on T cells and natural killer (NK) cells.
Allison was the first person to isolate the T-cell antigen receptor
protein, a breakthrough which has been called one of the three most important findings in immunology in the last 20 years.
6, 2015 /PRNewswire/ -- A new study co-authored by Regional Cancer Care Associates (RCCA) researchers from the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and presented here at the American Society of Hematology (ASH) annual meeting demonstrates that chimeric antigen receptor
T-cell (CAR-T) therapy can induce remission of certain blood cancers that may progress after a patient receives stem cell transplantation, while reducing the risk of a potentially fatal post-transplant complication known as graft-versus-host disease (GVHD).